The study compares the efficacy and safety of the INBRX-106 combination therapy against pembrolizumab monotherapy in treatment-naïve patients expressing PD-L1 with a Combined Positive Score of at least 20. Designed to address the limitations of traditional bivalent antibodies, INBRX-106 uses a proprietary single-domain platform to achieve high-order receptor clustering, which the company claims is essential for robust T-cell activation and survival.

Investors can access the presentation through the company’s investor relations portal or by dialing 1-888-880-3330 using conference ID 6981384. Following the live session, the data and updated corporate slides will remain available on the Inhibrx website for 60 days. This clinical milestone represents a key assessment of the company’s multivalent approach to protein engineering, which also includes the development of ozekibart.